Fleischmann R
University of Texas, Dallas.
Eur J Rheumatol Inflamm. 1991;11(3):50-3.
Altogether 1,912 patients have been enrolled in studies of nabumetone in the United States. They were all patients with osteoarthritis or rheumatoid arthritis. After completing participation within randomised studies patients were entered into an open study which continued for up to five years. These cases provide longterm efficacy and safety data for the use of nabumetone. About 25% of patients were withdrawn because of lack of efficacy; most of these withdrawals were in the first year of therapy. There was a similar picture with side-effects. About 12% of patients were withdrawn, mostly in the first year. Many patients continued to take nabumetone for five years without adverse effects and with continuing efficacy. The numbers of patients in whom nabumetone was stopped due to lack of efficacy or an adverse reaction was similar in those aged over 65 years and in patients aged less than 65 years. These results show that nabumetone is a safe and effective anti-inflammatory drug in long term clinical use.
在美国，共有1912名患者参与了萘丁美酮的研究。他们均为骨关节炎或类风湿关节炎患者。在完成随机研究的参与后，患者进入一项开放研究，该研究持续了长达五年。这些病例提供了萘丁美酮使用的长期疗效和安全性数据。约25%的患者因疗效不佳而退出；这些退出者大多在治疗的第一年。副作用方面情况类似。约12%的患者退出，大多也是在第一年。许多患者持续服用萘丁美酮五年，无不良反应且疗效持续。因疗效不佳或不良反应而停用萘丁美酮的患者数量在65岁以上患者和65岁以下患者中相似。这些结果表明，萘丁美酮在长期临床使用中是一种安全有效的抗炎药物。
